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Abstract

Growth factors are found in most of the organisms including insects, humans, plants, etc. The name ‘growth
factors’ became known when the substances were active in stimulating the growth of cells and tissues.
Growth factors are regulatory species (signaling molecules mainly proteins) that are generated by the
body which function in binding to receptors on the cell surface and are required to stimulate the growth
in living responsive cells by triggering cellular proliferation and/or cellular differentiation pathways,
as well as by regulating gene transcription in the nucleus. They are quite versatile by promoting cell
growth and act in a paracrine, retrocrine, autocrine, or juxtacrine signaling pathways. Cellular division
is stimulated by growth factors in different cell types, while others can be specific to a cell type. Every
growth factor binds to a specific receptor on the cellular surface. Cytokines are a family of growth
factors that help in stimulating the movement of cells towards inflammatory sites, trauma, and infection.
Abnormal regulation and production of growth factors and cytokines tends to cause various diseases that
include, but are not limited to, cancer, diabetes, liver fibrosis, and bronchopulmonary dysplasia. A critical
discussion with a focus on the diverse role and abundance of front-line growth factors in human body is
presented. Bio-pharmacological relationships between growth factors with several diseases have also
been incorporated in this article.
Keywords: Growth factors; Cell proliferation; Cellular differentiation; Cytokines; Fibroblast

Introduction
Growth factors were discovered when investigators studied biological substance effects
on cells and tissues in cultures, identified an assembly of substances that were peptidehormone-like which were different from any hormones previously known. The similarity of
growth factors with hormones is that some growth factors can be secreted into the blood
stream, transporting them to their tissues. However, the production of hormones is strictly
limited to glandular tissue. On the other hand, many types of tissues can produce different
types of growth factors. An example of a class of signaling proteins that can act as growth
factors are cytokines. They are used widely in cellular communication, in the function of
the immune system, and in embryogenesis. In the past, growth factors and cytokines were
thought to respectively serve as cell growth components and immunological response
factors [1]. Most recently, research has stated that growth factors for example cytokines
can have similar functions and can be used interchangeably. There are several different cellsignaling mechanisms are used to best suite its purpose. Paracrine signaling occurs between
neighboring cells where the signals get quick responses and last only a short amount of time
due to the degradation of the paracrine ligands [2,3]. In autocrine signaling, a cell signals itself
through a component that synthesizes, leading to a biological response within the same cell. In
endocrine signaling, growth factor and cytokine components are secreted into the blood and
are then carried by blood and tissue fluids on to target cells where by subsequent responses
are triggered [3]. Growth factors can also be divided into various families or super families
based on structural and functional characteristics. An example of a major growth factor family
is the transforming growth factor-β (TGF-β superfamily). TGF-β was originally characterized
as a protein that was capable of inducing a transformed phenotype in non-neoplastic cells in
culture. In TGF-β, all the family members have dimeric structures and their heterodimeric
receptor complexes are consisted of type I and type II receptor subunits with serine/
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threonine kinase domains. Within the family, complex interaction
remains the same. Following ligand binding, the type I receptor
is phosphorylated and stimulated by the type II receptor, which
then activates a Smad-dependent signaling pathway, regulating
gene transcription [3]. For research purposes, growth factors are
used in cell models to study their functions, and their signaling
pathways. Based on their roles, many growth factors in cytokines
have also been utilized for preclinical and clinical applications.
Recombinant human platelet-derived growth factor (PDGF) is an
example of a growth factor, made by platelets in blood clots, and
has been used to stimulate angiogenesis, migration, and mitosis
in mesenchymal cells in preclinical studies. Although clinical
applications of cytokines are considered as standard treatment for
certain diseases but there are also side effects associated with this
treatment. As an example, the administration of granulocyte-colony
stimulating factor (G-CSF) has been reported to cause osteoporosis,
acute coronary syndrome, and bone marrow necrosis. High
quality growth factors must pass various quality control testing
for purity, quantification, and activity. Purity tests, such as SDSPAGE can determine the possible contamination with non-specific
proteins, and/or endotoxins that can trigger undesirable effects
such as cell differentiation. Quantification is used to achieve
product size and results. Commonly used protein quantification
methods are Bradford colorimetric dye, UV-visible spectroscopy,
and Densitometric comparison. Growth factor activity is tested
through specific bioassays that determine the relative strength of
the growth factor to a standard [1-3].

Growth Factors: Major types
There are various kinds of growth factors that exist, and several
were initially isolated from animal tissues, including cattle and
mice. Insulin-like growth factors are examples of these substances
because they stimulate growth by growth hormone secretion from
the pituitary gland; the epidermal growth factor, which stimulates
the growth of epidermal cells; the nerve growth factor, which
stimulates the growth of neuronal cells, and lastly, the plateletderived growth factor, which stimulates the growth of connective
tissue cells and also muscle cells. Insulin-like growth factor I is also
called somatostatin C, IGF-I. This hormone is widely discussed for
possible performance enhancement and shares the common name
“insulin” which is the medication used to treat type I diabetes [4].
The secretion of IGF-I is regulated by human growth hormone,
which is produced by the pituitary gland. IGF-I is produced,
secreted primarily from the liver. There are other peripheral tissues
such as bone, that produces its own IGF-I. The reason behind
the name of IGF-I is that it has insulin like subunit that binds to
insulin receptors, but it only has 10% of the potency of regular
insulin on glucose regulation. Insulin-like growth factor I (IGF-1)
is an anabolic hormone, meaning it promotes growth. It includes
skeletal muscle and it is not androgenic, as opposed to testosterone
which indicates that it does not promote male sex characteristics
such as facial hair, deep voice, etc. The side effects of IGF-I are low
blood sugar, retinal edema, severe muscle pain, and bell’s palsy
[1,4]. Figure 1 summarizes the relationship of IGF-1 with various
cellular/physiological processes.

Insulin-like Growth Factor-1
(IGF-1)

Erythropoiesis

Muscle
Protein synthesis
Cell growth
Glucose homeostasis
Angiogenesis
Apoptosis

Brain
1. Growth of neuron
2. Dendritic arborization
3. Synaptogenesis

Bone
Mass & Density

Figure 1: Multidirectional functions of Insulin-like growth factor 1 (IGF-1).
Growth factors play key roles in human body. The major
primary effect is growth stimulation; it affects all tissues equally in
the body, not just skeletal muscle, and occurs because it is released
in the blood stream by the liver. Other functions include whole body
protein synthesis, and inhibition of protein breakdown, low blood
Cohesive J Microbiol Infect Dis

sugar, increased kidney filtration, enhanced bone mineralization,
and more. Its function overlaps with human growth hormone
(HGH). HGH is a hormone that is responsible for the production of
growth factors and perform various functions in the human body
including developmental and operational functions. After maturity,
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approximately around age 20, the HGH that the body produces
declines naturally and dramatically, but HGH is still necessary during
adulthood in order for growth, cellular repair and regeneration to
occur. However, HGH is not a good performance enhancer because a
recent study found where the supplementation of growth hormone
is no more effective at skeletal muscle growth than a placebo. The
side effects of HGH include arthralgia, arthritis, enhanced heart,
muscle weakness, high cholesterol, impaired glucose regulation and
increased risk of type I diabetes, impotence, and increased fatigue
[4]. As it has been mentioned earlier, growth factors act as typical
signaling proteins and are also capable to regulate/contribute in
several dreadful diseases like cancer, diabetes, HIV, cardiovascular
diseases and so on. A brief account elaborating the influences of
growth factors on these diseases are presented in the sequel.

Role of growth factors in Cancer

Growth factors frequently are involved in the production
of resistance to therapeutic procedures, prolonging the role of
polypeptide factors to precise late stages of tumor development
and offering opportunities for cancer therapy. Studies done in the
early 1950’s were one first occurring lines of evidence regarding
cancer with soluble growth factors. The mechanisms that allow limb
innervation in chick embryos, and transplanted a lump sarcoma
found on a mouse onto an embryo were studied by observing
thorough attraction of nerve fibers to the sarcoma lump. Later, a
venom from a snake was identified and the murine submaxillary
gland secreted a particularly active “nerve-stimulating factor”, that
began with the isolation of the first growth factors: Nerve Growth
Factor (NGF) and Epidermal Growth Factor (EGF). It was reported
that cells that were infected by the ‘feline sarcoma virus’ lost their
ability to bind EGF, leading to the isolation of a murine sarcoma of
two “transforming growth factors”, TGF-α and TGF-β [5,6].
Cancer drugs are the focus of intense clinical investigation.
Angiogenesis is mainly driven by 3 angiokinase pathways and is
critical for diseases such as solid cancers, where new blood vessels
deliver oxygen and nutrients to tumors, enabling tumor growth
and metastasis. Blood vessels are composed of many cell types,
that include endothelial cells, smooth muscle cells, and pericytes.
Three signaling molecules that activate receptor tyrosine kinases
on pericytes, vascular smooth muscle cells, and endothelial cells
in order to initiate important proangiogenic signaling cascades
are fibroblast growth factor (FGF), platelet-derived growth factor
(PDGF), and vascular endothelial growth factor (VEGF). VEGF
and FGF stimulate endothelial cell growth migration and survival,
critical for new blood vessel formation. PDGF stimulates pericyte
recruitment, that is needed for normal microvascular stability
and function. PDGF is also identical to the RNA tumor virus called
simian sarcoma virus. PDGF and FGF stimulate smooth muscle
cell recruitment, critical for maturation and maintenance of
blood vessels. All three growth factors are crucial to blood vessel
formation maintenance and integrity [5,6].
VEGF is a homodimeric glycoprotein and a predominant
angiogenesis pathway that is a target for anticancer therapy,
making it the most important growth factor. The reason being
Cohesive J Microbiol Infect Dis
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is that its angiogenesis-promoting activity is at the level of the
endothelial cell, and tumor penetration is less critical for VEGF
inhibitors because it is compared with agents that directly target
tumor cells. Tumors can activate alternative or escape mechanisms,
and can upregulate FGFR, either spontaneously or during VEGF
blockade. The result of the “angiogenic switch” is caused by the
production of VEGF and other growth factors by the tumor, making
it grow exponentially and leading to high interstitial pressure.
Many biomarkers have been recognized as prognostic effectors
and novel metastatic markers, targeting biomarkers such as
growth factors and chemokines in gastric cancer (GC). In addition,
tumors overexpress FGFR and PDGFR, representing a direct target
for growths inhibiting FGFR and/or PDGFR by blocking all three
angiokinase pathways, and making an approach to affect tumor
growth by inhibiting critical steps in angiogenesis, increasing
the effectiveness of chemotherapy and radiotherapy. Through
several studies it was suggested that triple angiokinase inhibition
may prevent further tumor growth and related tumor escape
mechanisms. Bevacizumab is a humanized monoclonal drug that
is used to treat several types of cancers and is directed at VEGF,
making it the most advanced in clinical development by making
VEGF a rational focus for anticancer therapy, showing promising
results in clinical trials [6,7].
About 1.6% of the 22,000 functional genes in the human genome
display intermittent somatic mutations in cancer. It should be
considered that genes in the pathways are due to driver mutations
not being able to interrupt on more than one gene in a pathway.
Few gene families inside protein kinase descends that are placed
downstream of growth factor receptors are frequently mutated
in certain tumors. For example, pancreatic (RAS), melanomas
(B-RAF), brain cancer (EGFR), and breast (ErbB-2/HER2). However,
co-existence of such mutations and driver mutations that directly
affect growth factor genes are very rare [8].
Prostate cancer (PCa) is the most common type of cancer in
males. Recent studies suggest patients who have diabetes and take
metformin (MF), have a lower chance of getting PCa. MF helps by
lowering blood glucose levels, preventing the liver from making
additional glucose. The growth factor, IGF-1 causes production and
growth of PCa and MF has antineoplastic effects like adenosine
monophosphate-activated protein kinase (AMPK), which is the
suppression of androgen signaling pathways. Conveyance of metaanalysis proposes mortality benefit to patients who display PCa
when taking MF, improved significantly [9].

Role of growth factors in Diabetes

Type 1 diabetic mellitus (T1DM) is known to adversely affect
pubertal development and linear growth. Insulin-like growth
factor-1 (IGF-I) is an extension of a growth hormone and seems
to be associated in the earlier stages of the disease. Low levels of
IGF may be linked to increased secretion of growth hormones in
people with type 1 diabetes. IGF-1 is produced in the liver as an
endocrine hormone and in target tissues. The production IGF-1 has
the highest rates during pubertal growth spurt and have the lowest
levels in infancy and old age. The growth hormone concentration
Copyright © : Debasish Bandyopadhyay
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in people who have diabetes are generally 3 to 4 times higher than
people who do not have the disease. Abnormal levels of IGF and
growth hormones may also increase the chances and complications
of diabetes. Growth hormone has a pulsating secretion with agedependent concentrations that are characterized by mediocre
secretion in the pre-pubertal period, a rise at puberty, and a
reduction in old age. Results of clinical trials evaluating IGF-1in
both type 1 and type 2 diabetes showed a great result in reduction
of hemoglobin A1C levels, and daily insulin consumption. Insulinlike growth factor-binding protein (IGFBP-3) is an abundant protein
that is encoded by the IGFBP3 gene and is the most important ICFP
circulating during early age and is growth hormone dependent.
IGFBP-3 carries IGFs to the target tissues and prolongs the halflife of IGFs, making a ternary complex with acid labile subunit
(ALS), which have an important role in the management of skeletal
growth. Studies have shown and proved that insulin regulates
the hepatic growth hormone receptor expression to influence the
serum concentrations of IGFs and IGFBPs [4,10,11].

The structural changes that characterize diabetic
microangiopathy ‘abnormal growth’ and ‘impaired regeneration’
strongly suggest a role for several irrationally expressed
growth factors that can possibly lead to the development of the
complications. Increased concentrations have been detected and
have occurred in some growth factors targeting tissues of longterm diabetic complications, enhancing the expression of the
growth factors. They activate the biochemical pathways that link
hyperglyceaemia to microvascular changes: vasoactive hormones;
hyperglyceaemia pseudohypoxia; non-enzymatic glycation of
proteins; oxidative stress, and the polyol pathway. The transforming
growth factors beta (TGF-βs) are involved in both the early and
late stages and is accountable for extracellular matrix (ECM)
accumulation. VEGF, PDGF, and bFGF (basic fibroblast growth
factor) also play crucial role in non-proliferative retinopathy as well
as proliferative retinopathy. VEGF is the growth factor that is most
closely correlated with neovascularization. The failure of numerous
neurotrophic factors, IGF-I, and nerve growth factor (NGF) have
been related to the deterioration or impaired alteration that occur
in diabetic neuropathy. The liver is very vital in protecting you
against diabetes. The three things that lower IGF are insulin, stress,
and estrogen. Exercise, intermediate fasting, and sleep will trigger
IGF [12,13].
Diabetic retinopathy can have sight-threatening complications,
including preretinal neovascularization and chronic retinal
oedema. Growth factors have been involved in the pathogenesis of
ocular neovascularization because of the association with retinal
ischaemia. The ischaemic retina secrete growth factors, stimulating
residual vessels to grow rapidly. It has been found that many growth
factors are manufactured during the neovascular process, resulting
in limited effects of their specific inhibition. Laser photocoagulation
of the retina is currently the only treatment for proliferative diabetic
retinopathy because the regression of new vessels has been proven
beneficial, possibly through the destruction of the ischaemic retina,
which produces neovascular growth factors [13,14].
Cohesive J Microbiol Infect Dis
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Relation between growth factors with HIV and AIDS
Human immunodeficiency virus (HIV) infection is associated
with multiple defects in hematopoiesis and immune regulation.
Over 36.9 million people were living with HIV/AIDS in 2017,
which is the latest data available. 21.7 million people accessed
antiretroval therapy (ART) in 2017 [15,16]. The deficiencies
decrease the proliferation of hematopoietic progenitor cells (IGF-I,
IGF-II, and IGFBP3), and a boost in the destruction of mature cells
(IGFBP1 and IGFBP2). IGF-I levels are a warning sign because it
increases the risk of potential adverse effects, such as malignancy
or acromegalic-like symptoms. IGF-I levels can increase with other
hormones such as erythropoietin for the treatment of anemia or
anabolic androgens that have been used in other patients [17].
Hematopoietic growth factors are a successful approach to the
management of clinical problems. Till date three major agents
have been demonstrated therapeutic potential against HIV in
clinical trials. In a phase I trial, granulocyte macrophage-colony
stimulating factor (GM-CSF) improved pre-existing neutrophil
defects and leukopenia in patients with HIV infection. In a placebocontrolled trial, erythropoietin (EPO) decreased the transfusion
requirements and corrected anemia in patients who were obtaining
zidovudine. In a phase I/II trial, granulocyte colony-stimulating
factor (G-CSF) also corrected neutrophil defects and leukopenia in
patients with AIDS excluding the alteration of HIV expression. In
both treatments, G-CSF and EPO improved leukopenia and anemia,
reducing the toxicity of zidovudine. There have been new solutions
of hematopoietic stimulants that are being used to compress the
toxicity from cytotoxic chemotherapy in the treatment of AIDSrelated malignancies [17,18].
Cytokines are involved in the pathogenesis of disease
progression and in the treatment of HIV. The primary role of
cytokines is to regulate blood cell production and have been
examined significantly in HIV positive patients. Granulocytemacrophage colony-stimulating factor (GM-CSF), Granulocyte
colony-stimulating factor (G-CSF), and IL-3 have been classified as
treatments to improve the count of low blood cells that accompany
AIDS. Peripheral blood cytopenia is one indication of HIV infection
that has a decline in blood cell counts, resulting in immune function
weakness. CD4+ lymphocytes are one of the cell types that decrease
in number during HIV disease breakthrough [19].
A study performed in 2016 for reciprocal effects of “antiretroviral
drugs” were used to treat HIV infection on FGF21/β-Klotho (KLB)
System. Antiretroviral therapy (ART) uses HIV medicines to treat
HIV (it is not a cure for the disease) and helps people live longer and
healthier. It is recommended for everyone who has HIV infection to
start ART as soon possible. In antiretroviral therapy (ART), results
showed that HIV-infected patients showed high circulating levels
of FGF21 but in contrast, β-Klotho was reduced in target tissues,
making HIV a chronic medical condition. The high levels of FGF21
in HIV patients are associated with altered bone homeostasis. In
present studies, the effects of FGF21 and KLB for antiretroviral
treatments resulted in induction of FGF21 levels and suppression
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of KLB expression; reflecting the effects of gene transcription. The
alterations in the FGF21/KLB system that was found in HIV patients
should be improved by minimizing adverse effects of antiretroviral
agents in patients that are infected with HIV [20-23].

Growth factors and Central Nervous System (CNS)

There are quite a few major classes of growth factors which act
within the nervous system. Fibroblast growth factors (FGFs) are a
family of growth factor signaling proteins that have multiple roles
and are involved in angiogenesis, embryonic development, and
signaling pathways. They also regulate developmental processes
and the physiology of adults. There are members of FGF that have
multiple roles and there are partially 22 members of the FGF family.
10 of them are expressed in the developing CNS, and within these
10, there are four FGF receptors (FGFR-1-4). Fibroblast growth
factors -2 and -15 are commonly expressed throughout the evolving
CNS. FGF-8 and FGF-17 are restricted into a specific region in the
developing brain and those two are only expressed in the embryo
during the early phases of neurogenesis and proliferation. FGFR1 is the growth factor that is expressed the most, while FGFR-2
and FGFR-3 show patterns that change expression throughout the
central nervous system development. Most FGFs are fundamentally
secreted using the Endoplasmic Reticulum-Golgi secretory pathway
[24].
Secreted FGFs signal to target cells by binding and activating
cell-surface tyrose kinase FGF receptors. FGFRs are transcribed
from four different genes and consist of a single transmembrane
domain, a cytoplasmic tyrosine kinase domain and an extracellular
domain. There are three immunoglobin-like domains that the
extracellular domain contains, named loops I, II, and III. Loops II
and III attach to the bound ligand, COOH-terminal portion of loop
III is the region that dictates binding in a specific matter. Another
mRNA merging of the COOH-terminal portion of loop III constructs
some forms of FGFRs with extremely unique ligand-binding
properties. The receptor combines with a molecule to form a dimer
and phosphorylates intermolecular tyrosine residues after an
FGF ligand is bound, resulting in initiation trigger of FGFR signal
transduction. The signaling of FGFR activates numerous of signal
transduction molecules like: phospholipase C-γ pathways and Ras.
FGF12 and FGF14 interact with the “mitogen-activated protein
(MAP) kinase scaffold protein Islet-Brain-2 neurons” [24,25].
The binding of ligands is affected by distributing the heparin
sulfate proteoglycans (HSPGs) on the cell surface and in the
extracellular matrix. Extracellular FGFs bind firmly to HSPGs. HSPGs
may interact with receptors on nearby cells and restrict diffusion,
and favor interaction. Lastly, HSPGs promote and keep assembly
in a steady state of the FGF ligand-receptor complex. Studies have
shown that Xenopus embryos’ initiation of posterior neural tissue
that is arbitrated by the transcription factors XBF2 and Xmeis3
depends upon the activation of the FGF signaling-dependent-RasMAP kinase pathways. Studies on chicken embryos that have shown
that progress of posterior neural tissue is promoted by FGFs while
maintaining the proliferating neural progenitors which contribute
to posterior CNS development [4,24,25].
Cohesive J Microbiol Infect Dis
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Role of growth factors in Cardiovascular Diseases
Fibroblast Growth Factors (FGFs) have recently been studied
completely as some potentially new molecules in order to prevent
and help treat cardiovascular disease, angiogenic actions, and
attribute to metabolic effects. Members of the endocrine FGF
family have been shown to increase metabolic rate, restore glucose
homeostasis, and decrease adiposity. FGF serum levels have been
related with well-known cardiovascular risk factors as well as with
the severity and extent of coronary artery disease (CAD) and is also
used to predict cardiovascular death. Clinical trials have examined
FGF administration for therapeutic angiogenesis in ischaemic
vascular disease. This demonstrates a possible role in order to
improve ischaemic chest pain and limb function. Also, FGF21
is the most recent member of the FGF family and has recently
developed as a potent metabolic regulator with multiple effects
that have improved the lipoprotein profile. This may be very useful
as markers of cardiovascular risk and can work as a therapeutic/
protective agent in cardiovascular disease [26].
FGF23 is a member of the endocrine FGFs and a recent large
study was performed where the increased FGF23 levels were
combined with cardiovascular death, including an incident heart
failure in 3,627 patients with stable ischemic heart disease. There
was a better response to therapy with angiotensin-converting
enzyme inhibitor therapy with FGF23 levels. The link of FGF23 with
direct cardio effects, including possible connotation of serum levels
with cardiovascular risk factors are currently still being researched
[26,27].

Growth factors and Parkinson’s Disease

Parkinson’s disease is a progressive and chronic disorder of the
nervous system that affects movement of the body. It is one of the
most frequent neurodegenerative disorders in humans. The cause
for the disease is not clear, and no known cure has been found, but
there are treatment options like medication and surgery in order to
improve the symptoms. Brain-derived neurotrophic factor (BDNF)
are critical modulators in maintenance and neurodevelopment of
both the CNS and PNS that advocate for the survival of neuronal cells
in production. These factors can likely be a potential therapeutic
target in order to treat Parkinson’s disease (PD). In clinical trials, it
has been reported that BDNF have been considered central in new
therapeutic strategies, which can either ease or reverse the harmful
symptoms in advanced Parkinson’s disease [28,29].

Growth factors and Alzheimer’s Disease

Alzheimer’s disease (AD) is the most common form of dementia
that causes problems with a decline in memory, thinking and
behavior. Symptoms of Alzheimer’s develop slowly and worsen
over time, making it difficult to complete daily tasks. It affects more
than 5.5 million Americans, about 30% of elders over 75 years old
- making it the sixth leading cause of death in the U.S. There is no
cure for AD, but treatments and research continue [30]. Cholinergic
basil forebrain (CBF) neurons are important in pathogenesis
of Alzheimer’s and are very dependent on nerve growth factor
(NGF), which has been projected as a potential therapy for AD by
Copyright © : Debasish Bandyopadhyay
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slowing the progression of the disorder due to its effects on the
CBF. Amyloid- β (Aβ) is known to impair communication between
neurons, resulting in neurodegeneration. The Aβ peptides lead to
deposition of senile plaques and decline the cognitive functions.
Familial Alzheimer’s result from mutations in the gene for
amyloid-β protein precursor or enzymes generated by Aβ [31]. It is
possible for Aβ to accumulate in people with no family history of the
disease, making the cause of intermittent AD less clear. Studies have
shown that Aβ42 is necessary in the pathogenesis of Alzheimer’s
due to its senile plaque deposits by increasing the expression of
genes in neuroblastoma cells like insulin-like growth factor binding
proteins 3 and 5 (IGFBP3/5). The IGFBP’s showed increase in vivo
concentrations of human AD cerebrospinal fluid and are modulated
by Aβ42, making it a beneficial early biomarker [32].

Growth factors and Chronic Kidney Diseases

FGF-19, FGF-21, and FGF-23 are three members of the fibroblast
growth factor (FGF) family. They are endocrine factors that act in
regulating several metabolic processes. They do not have FGFRs
(FGF receptors), but instead have binary complexes of FGFRs and
Klotho proteins. FGF-23 and FGF-21 are biomarkers that start to
increase in early-stage CKD (chronic kidney disease). FGF-23 is a
hormone that is mainly derived from bone, binding to α-Klotho,
a transmembrane protein [22]. The physiological functions of
FGF-23 are mediated from both FGF-23 and α-Klotho by forming
a trimeric signaling complex, allowing to circulate and activate
FGFR/ α-Klotho complexes permitting the renal tubules to increase
the excretion in phosphate per neuron. In order to maintain the
phosphate balance, a decrease in the nephron during the chronic
kidney disease progression must be active while having an increase
the FGF-23 necessary for compensation [22,33]. Nephron loss can

be accelerated by inducing renal tubular damage by an increase
in phosphate excretion per nephron [34]. CPPs (calciprotein
particles) are a complex of calcium and phosphate nanoparticles
that induce impairments such as endothelial damage and
inflammatory responses [35]. CKD progression is associated by the
increase of CPPs in the blood, resulting in cardiovascular disorders.
Causes include CKD-MBD (CKD-mineral and bone disorder) which
results in calcification of soft tissue due to damaged calcium and
phosphorus metabolism. FGF-23 is elevated in CKD-MBD. FGF-21
is a liver-derived hormone that binds to βKlotho-FGFR complex
that is responsible for inducing stress responses in the CNS (central
nervous system), activating the SNS (sympathetic nervous system)
and the hypothalamus-pituitary-adrenal axis. The most effective
way for refining clinical outcomes through enrichment of CKD-MBD
would include surgical interventions, which would help reduce
levels of FGF-23 and CPPs [34,35].

Growth factors and Platelet-Rich Plasma (PRP)

Growth factors might have several future implications including
platelet-rich plasma. Platelet-rich plasma (PRP) is a substance that
promotes soft tissue healing when injected. Platelets are important
reservoirs of growth factors and the role of plasma is to help blood
clotting by special factors or proteins while also supporting cell
growth. PRP has been produced by isolating plasma from blood and
concentrating it. A few examples of PRP injections have been used
for hair loss, tendon injuries, acute injuries, postsurgical repair,
osteoarthritis, and more [36-39]. The following growth factors are
contained in the α-granules of platelets: Platelet-Derived Growth
Factor (PDGF), Transforming Growth Factor (TGF), Platelet-Derived
Angiogenesis Factor (PDAF), Interleukin (IL), Vascular Endothelial
Growth Factor (VEGF) (Figure 2).

Transforming
growth factor β-1
(TGFβ-1)
Platelet derived
growth factor (PDGF)

Vascular endothelial
growth factor (VEGF)

Platelets

Fibroblast growth
factor (FGF)

Epidermal growth
factor (EGF)

Keratinocyte
growth
factor (KGF)
Figure 2: Platelet-rich plasma (PRP)..
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The clinical effectiveness of platelet concentrates as:
Autologous Platelet-Rich Plasma (APRP) depend mainly on the
concentration of growth factors, as well as the number of platelets,
acting as transmitters such as tissue healing and making them
responsible for proliferation, chemotaxis, tissue morphogenesis,
and differentiation. Studies on the effect of PRP in hair regrowth
by injecting PRP which induced proliferation of dermal papilla cells
by upregulating FGF-7, extracellular signal-related kinase (ERK),
β-catenin, and Akt signaling. An important factor in hair growth
is anagen-associated angiogenesis due to the secretion of VEGF by
the fibroblasts of dermal papilla and keratinocytes of outer root
sheath. By injecting the PRP into the scalp, researchers were able
to demonstrate improvement in cutaneous ischaemic conditions,
epidermis thickness, and an increase of hair follicles after PRP
treatment [40-42].

Conclusion

Growth factors are part and parcel in human life. They are able
to initiate/propagate/maintain and terminate various cellular
mechanisms. Subsequently, growth factors play important role
from cell division/cell growth to cell death. Although several
research projects are being conducted around the world but more
research is required to understand versatile roles and functions of
growth factors in human body.
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